Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | MAX | P61244 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30806338 | 0.82 | MEN1 (0.46) | MAPTKMT2AMEN1GAAALDH1A1 | |
| SCHEMBL30806443 | 0.82 | ALDH1A1 (0.47) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL6944865 | 0.78 | MAPT (0.64) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL3021466 | 0.75 | MAPT (0.70) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL30806493 | 0.74 | ALDH1A1 (0.43) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL10385892 | 0.74 | MAPT (0.72) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL3031076 | 0.74 | MAPT (0.72) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL6941586 | 0.73 | MAPT (0.58) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL6941411 | 0.73 | MAPT (0.58) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL6941409 | 0.73 | MAPT (0.58) | CTSVCTSLMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | CTSV 2685/4885CTSL 3068/4885MAPT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.